Recursion has received orphan drug status from the FDA for its small molecule allosteric inhibitor MEK1 and MEK2, REC-4881. The drug is a potential drug for familial adenomatous polyposis. The company expects within 9 months to start enrolling participants for a Phase II clinical trial.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept